# Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

> **NCT04462471** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Thyroid Carcinoma
- Thyroid Cancer
- Thyroid Cancer, Follicular
- Thyroid Cancer (Follicular Cell)
- Thyroid Cancer, Papillary
- BRAF V600E Mutation Positive

## Interventions

- **DIAGNOSTIC_TEST:** I-124 PET/CT lesion dosimetry
- **DRUG:** Vemurafenib
- **DRUG:** Copanlisib

## Key facts

- **NCT ID:** NCT04462471
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-26
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462471, "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04462471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*